Protéine de fusion ou anticorps monoclonal
Author:
- 15 December 2009
- journal article
- research article
- Published by EDP Sciences in médecine/sciences
- Vol. 25 (12) , 1033-1038
Abstract
Therapeutics options for inflammatory diseases, such as rheumatoid arthritis (RA), have increased tremendously in the past decade with the introduction of biologic therapies, such as monoclonal antibodies or recombinant fusion proteins. These have proven to be highly successful in treating inflammatory or autoimmune diseases, by blocking certain key molecules involved in the pathogenesis of the illness, cytokines (TNF) or immune coactivators (CTLA-4). Thus in rheumatoid arthritis, TNF can be neutralized both by monoclonal antibodies (adalimumab, infliximab) or recombinant inhibitors such as etanercept or CTLA-4 Ig abatacept. All have been marketed and proven to be highly effective in the treatment of RA, and we will discuss parameters which are taken into account to select monoclonal antibody or recombinant inhibitors. These include drug-related (target affinity, pharmacokinetics, mechanisms of action, etc.) and patient - (efficacy and side effects) or disease-related characteristics. Their impact on current clinical practice and future trends are discussed.Keywords
This publication has 41 references indexed in Scilit:
- Risk of tuberculosis is higher with anti–tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three‐year prospective french research axed on tolerance of biotherapies registryArthritis & Rheumatism, 2009
- Mathematical modeling of the cause of tuberculosis during tumor necrosis factor blockadeArthritis & Rheumatism, 2008
- Tumor necrosis factor antagonist mechanisms of action: A comprehensive reviewPharmacology & Therapeutics, 2008
- Characterization of a complex glycoprotein whose variable metabolic clearance in humans is dependent on terminal N-acetylglucosamine contentBiologicals, 2008
- Tumor Necrosis Factor Receptor 2–Mediated Tumor Suppression Is Nitric Oxide Dependent and Involves AngiostasisCancer Research, 2007
- F.76. Differential TNF-Neutralizing Potencies of Adalimumab, Etanercept and InfliximabClinical Immunology, 2006
- Etanercept induces apoptosis of dermal dendritic cells in psoriatic plaques of responding patientsJournal of the American Academy of Dermatology, 2006
- Blockade of lymphotoxin pathway exacerbates autoimmune arthritis by enhancing the Th1 responseArthritis & Rheumatism, 2005
- Reverse signalling of membrane‐integrated tumour necrosis factor differentially regulates alloresponses of CD4+ and CD8+ T cells against human microvascular endothelial cellsImmunology, 2005
- Compromised Function of Regulatory T Cells in Rheumatoid Arthritis and Reversal by Anti-TNFα TherapyJournal of Experimental Medicine, 2004